Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
Medical Journal of Australia · 05.02.2024 · 220 (2) · 80-90
DOI: 10.5694/mja2.52199 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medical Journal of Australia, online erschienen am 11.01.2024. Verfasst von Luke S McLean und 18 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, VIC. Hauptthemen laut MEDLINE: Skin Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Objectives
To review the outcomes of immune checkpoint inhibitor (ICI) treatment of advanced cutaneous squamous cell carcinoma (CSCC) outside clinical trials. Study design Retrospective observational study; review of patient records in fifteen Australian institutions. Setting, participants All Australian adults with locally advanced or metastatic CSCC not amenable to curative surgery or radiotherapy treated with ICIs, 5 May 2017 – 23 May 2022, through a cemiplimab compassionate access scheme (Therapeutic Goods Administration Special Access Scheme) or who personally covered the cost of pembrolizumab prior to the start of the access scheme. Main outcome measures Best overall response rate (ORR) according to standardised assessment criteria using the hierarchy: Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the modified World Health Organization clinical response criteria, and the Positron Emission Tomography Response Criteria (PERCIST 1.0); overall and progression‐free survival.
Results
A total of 286 people with advanced CSCC received ICI therapy during May 2017 – May 2022 (cemiplimab, 270; pembrolizumab, 16). Their median age was 75.2 years (range, 39.3–97.5 years) and 232 were men (81%); median follow‐up time was 12.2 months (interquartile range, 5.5–20.5 months). Eighty‐eight people (31%) were immunocompromised, 27 had autoimmune disease, and 59 of 277 (21%) had ECOG performance scores of 2 or 3. The ORR was 60% (166 of 278 evaluable patients): complete responses were recorded for 74 (27%) and partial responses for 92 patients (33%). Twelve‐month overall survival was 78% (95% confidence interval [CI], 72–83%); progression‐free survival was 65% (95% CI, 58–70%). Poorer ECOG performance status was associated with poorer overall survival (per unit: adjusted hazard ratio [aHR], 3.0; 95% CI, 2.0–4.3) and progression‐free survival (aHR, 2.4; 95% CI, 1.8–3.3), as was being immunocompromised (overall: aHR, 1.8; 95% CI, 1.1–3.0; progression‐free: aHR, 1.8; 95% CI, 1.2–2.7). Fifty‐five people (19%) reported immune‐related adverse events of grade 2 or higher; there were no treatment‐related deaths.
Conclusion
In our retrospective study, the effectiveness and toxicity of ICI therapy were similar to those determined in clinical trials. Our findings suggest that ICIs could be effective and well tolerated by people with advanced CSCC who are ineligible for clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peter MacCallum Cancer Centre, Melbourne, VIC.
- The University of Melbourne, Melbourne, VIC.
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC.
- Chris O'Brien Lifehouse, Sydney, NSW.
- Macquarie University, Sydney, NSW.
- Princess Alexandra Hospital, Brisbane, QLD.
ORCID-Profile: Luke S McLean
Förderung
- National Health and Medical Research Council
Zitieren
APA
McLean, L. S., Lim, A. M., Bressel, M., Lee, J., Ladwa, R., Guminski, A. D., Hughes, B., Bowyer, S., Briscoe, K., Harris, S., Kukard, C., Zielinski, R., Alamgeer, M., Carlino, M., Mo, J., Park, J. J., Khattak, M. A., Day, F., & Rischin, D. (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia, 220(2), 80-90. https://doi.org/10.5694/mja2.52199
Vancouver
McLean LS, Lim AM, Bressel M, Lee J, Ladwa R, Guminski AD, et al. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia. 2024;220(2):80-90. doi:10.5694/mja2.52199
BibTeX
@article{McLean2024,
author = {McLean, Luke S and Lim, Annette M and Bressel, Mathias and Lee, Jenny and Ladwa, Rahul and Guminski, Alexander D and Hughes, Brett and Bowyer, Samantha and Briscoe, Karen and Harris, Samuel and Kukard, Craig and Zielinski, Rob and Alamgeer, Muhammad and Carlino, Matteo and Mo, Jeremy and Park, John J and Khattak, Muhammad A and Day, Fiona and Rischin, Danny},
title = {Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study},
journal = {Medical Journal of Australia},
year = {2024},
volume = {220},
number = {2},
pages = {80--90},
doi = {10.5694/mja2.52199}
}
EUVIMED